Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?

In 1987, the government passed legislation to protect brand-name pharmaceutical firms against competition from generic drug brands in exchange for economic investment in Canadian pharmaceutical research and development (R&D). Since 2002, brand-name pharmaceutical companies' R&D investme...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shoo K., Mahl, Sukhy K., Green, Jessica J., Lexchin, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Longwoods Publishing 2023
Materias:
Discussion and Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019517/
https://www.ncbi.nlm.nih.gov/pubmed/36917450
http://dx.doi.org/10.12927/hcpol.2023.27038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019517/
https://www.ncbi.nlm.nih.gov/pubmed/36917450
http://dx.doi.org/10.12927/hcpol.2023.27038

Ejemplares similares